论文部分内容阅读
目的评价经导管超选择性插管治疗巨大肝海绵状血管瘤(CHL)的安全性及治疗效果。方法 27例直径大于5cm的巨大CHL患者,其中男性8例,女性19例;年龄38～64岁,平均年龄47.3岁。使用同轴微导管行超选择性插管,根据病灶大小采用平阳霉素、超液化碘油、2%利多卡因、庆大霉素制成乳剂12.5～22.5mL进行栓塞治疗,术后随访6～9个月。结果所有病例均治疗成功,术后6个月全部瘤体直径均小于4cm,25例肝血管瘤体积缩小大于50%,所有患者无严重并发症出现。结论经导管超选择性栓塞治疗巨大CHL安全性高,治疗效果好,应作为巨大CHL的首选治疗方法。
Objective To evaluate the safety and efficacy of transcatheter super selective catheterization in the treatment of giant hepatic cavernous hemangiomas (CHL). Methods Twenty-seven patients with giant CHL more than 5 cm in diameter were enrolled, including 8 males and 19 females, aged 38-64 years with a mean age of 47.3 years. The use of coaxial microcatheter super selective catheterization, according to the size of the lesion using Pingyangmycin, ultra-liquefied lipiodol, 2% lidocaine, gentamicin made emulsion 12.5 ~ 22.5mL embolization, postoperative follow-up 6 ~ 9 months. Results All the cases were successfully treated. All the tumor diameters were less than 4 cm at 6 months and the volume of 25 hemangiomas was reduced by more than 50%. No serious complications occurred in all patients. Conclusions Transcatheter superselective embolization in the treatment of giant CHL is safe and effective and should be considered as the first choice for treatment of huge CHL.